Professor Ruth Roberts, Dr Claire Sadler and Dr Leigh Ann Burns Nass present Target Safety Assessments: Knowledge is Power webinar in a SOT 2020 Exhibitor Hosted Session. Membership of SOT is not required. Registration for the webinar is free.
The meeting that ApconiX is co-organising the British Toxicology Society “Science-led Strategies for Success in Discovery and Development Toxicology” is being rearranged for a date later in 2020 - watch this space for updates! Sponsored by Lonza and AstraZeneca and co-organised by ApconiX, GlaxoSmithKline, Sygnature Discovery and Alderley Park, the meeting is focused on safety [...]
Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity
Abstract: Drug-induced liver injury (DILI) is of significant concern to drug development and regulatory review because of the limited success with existing preclinical models. For developing alternative methods, a large drug list is needed with known DILI severity and toxicity. We augmented the DILIrank data set [annotated using US Food and Drug Administration (FDA) drug [...]
Team ApconiX had a fabulous time at their Christmas party - secret Santa brought tears of laughter and sorrow and the odd gasp! A few team members went incognito. Wishing everyone a lovely holiday and the very best for the coming year. Looking forward to a new decade and new challenges. See you in 2020!
Professor Ruth Roberts, Co-Founder and Director of ApconiX will be speaking at the American Association of Pharmaceutical Scientists (AAPS) on Monday 4th November at 9:00am in a session entitled "Next Generation Technologies in Preclinical Development” chaired by Dr Shraddha Thakkar from the US FDA. Ruth’s talk is entitled “Science-Driven Design of the Preclinical Package: Case [...]
A thorough understanding of potential target-related effects is crucial to making the right choices in drug discovery. Experienced project toxicologists extract and interpret data from mouse knockouts, human gene mutations and known effects of modulators to determine the potential consequences of target inhibition or activation in each organ system. Target Safety Assessments are pivotal in [...]
Dr Kimberly Rockley and Professor Ruth Roberts had a fabulous time at the Gordon Research Seminar (GRS) and Conference (GRC) earlier this month. GRCs provide an international forum for the presentation and discussion of cutting-edge research in science; GRSs are organised by and for young investigators and take place alongside the GRC. L to [...]
We all know drug projects fail – so how can we improve our probability of success? TCP offers a systematic approach to de-risking projects by asking the right questions at the right time around target, chemistry and patient. For example, T: what are the safety implications of modulating the target? C: What are the likely [...]
Abstract: Parthenolide is a natural product that exhibits anti-leukaemic activity, however, its clinical use is limited by its poor bioavailability. It may be extracted from feverfew and protocols for growing, extracting and derivatising it are reported. A novel parthenolide derivative with good bioavailability and pharmacological properties was identified through a screening cascade based on in [...]
A great piece in the Financial Times this week “How Alderley Park Grew into an Innovation Hub” which highlights the success of Alderley Park following AstraZeneca’s announced departure 5 years ago. Ned Wakeman talks about his team’s continued support of the start-up companies and Dr Chris Doherty explains the vision of the site that will [...]